Incidence of Acetaminophen in Donated Blood

Sharon, R.; Menczel, J.; Kidroni, G.

doi:10.1159/000465373

Cited by 1 publication

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the latter no longer represents the standard preparation of modern blood banking [1,8,9,10]. On the basis of the results of Ferner et al [7] and taking into account further published evidence [8,9,11,14,15,16,18,19,20], we have proposed two approaches to deal with the problem of donor medication. Advantages of the ®rst approach, which guarantees a reduction of any donor medication to the level of 3% of the therapeutic drug concentration, are its simplicity, its wide safety margin and its easy applicability.…”

Section: Discussionmentioning

confidence: 99%

“…A careful interview on drug intake constitutes an essential part of any donor ®tness examination. However, the assumption that potential blood donors report their drug intake properly has been questioned repeatedly [3,4,5,18,19,20,21]. Mahnovski et al have shown that in 15% of random blood donors, drugs or their metabolites were assessable in the urine, despite reporting no drug use on being questioned [18].…”

Section: Discussionmentioning

confidence: 99%

“…Mahnovski et al have shown that in 15% of random blood donors, drugs or their metabolites were assessable in the urine, despite reporting no drug use on being questioned [18]. Sharon et al found that over 6% of plasma samples from donated blood contained acetaminophen, while salicylates were found in close to 8% [5,19]. In view of such data, donor plasma screening for penicillin, acetaminophen and other frequently used drugs has been suggested [4,5], but this approach is hardly practicable and far too expensive.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Blood donors on medication

Stichtenoth

Deicher

Frölich

2001

European Journal of Clinical Pharmacology

View full text Add to dashboard Cite

For drugs with known teratogenic risks, we suggest a deferral period of 28 plasma-elimination half-lives. For non-teratogenic drugs, a simple, conservative approach could be based on waiting for five plasma-elimination half-lives, thus reaching the required 3% safety level already in any donor. If, however, the type of blood component to be prepared is also considered, a more differentiated approach appears to be appropriate: for blood components containing 50 ml or less plasma from a single donor, donor medication may be disregarded because of the high dilution in the recipient's plasma volume, whereas for blood components with higher plasma contents (250 ml on average) from a single donor on medication the 3% safety level will be achieved by observing the deferral period of five plasma-elimination half-lives mentioned. A guideline for 191 drugs and drug classes has been elaborated accordingly.

show abstract

Section: Discussionmentioning

confidence: 99%